Autocrine GMCSF Signaling Contributes to Growth of HER2

Animals Autocrine Communication Breast Neoplasms / metabolism Cell Line, Tumor Cell Proliferation / genetics Cell Survival Disease Models, Animal Gene Expression Granulocyte-Macrophage Colony-Stimulating Factor / genetics Humans Meningeal Carcinomatosis / diagnosis Mice Oncogene Proteins / genetics Protein Kinase Inhibitors / pharmacology Receptor, ErbB-2 / metabolism Signal Transduction / drug effects Xenograft Model Antitumor Assays

Journal

Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R

Informations de publication

Date de publication:
15 09 2021
Historique:
received: 23 01 2021
revised: 29 05 2021
accepted: 08 07 2021
pubmed: 12 7 2021
medline: 4 1 2022
entrez: 11 7 2021
Statut: ppublish

Résumé

Leptomeningeal carcinomatosis (LC) occurs when tumor cells spread to the cerebrospinal fluid-containing leptomeninges surrounding the brain and spinal cord. LC is an ominous complication of cancer with a dire prognosis. Although any malignancy can spread to the leptomeninges, breast cancer, particularly the HER2

Identifiants

DOI: 10.1158/0008-5472.CAN-21-0259 PMID: 34247146 PMC: PMC8986153
pubmed: 34247146
pii: 0008-5472.CAN-21-0259
doi: 10.1158/0008-5472.CAN-21-0259
pmc: PMC8986153
mid: NIHMS1725465
doi:

Substances chimiques

Oncogene Proteins 0
Protein Kinase Inhibitors 0
Granulocyte-Macrophage Colony-Stimulating Factor 83869-56-1
Receptor, ErbB-2 EC 2.7.10.1

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

4723-4735

Subventions

Organisme : NCI NIH HHS
ID : K12 CA001727
Pays : United States
Organisme : NIGMS NIH HHS
ID : P20 GM104360
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA033572
Pays : United States

Informations de copyright

©2021 American Association for Cancer Research.

Références

Am J Cancer Res. 2013 Apr 03;3(2):117-26
pubmed: 23593536
Curr Cancer Ther Rev. 2011 Nov;7(4):319-327
pubmed: 23251128
Clin Biochem. 2018 Aug;58:122-124
pubmed: 29906422
Cancer Invest. 2005;23(2):145-54
pubmed: 15813508
J Clin Oncol. 2010 Jul 10;28(20):3271-7
pubmed: 20498394
Cells. 2019 May 16;8(5):
pubmed: 31100984
Curr Treat Options Neurol. 2007 Jul;9(4):283-93
pubmed: 17580008
Science. 2019 Jun 28;364(6447):
pubmed: 31249032
Clin Cancer Res. 2020 Jun 15;26(12):2789-2799
pubmed: 31969331
Oncotarget. 2016 Jan 26;7(4):3740-7
pubmed: 26543235
NPJ Precis Oncol. 2018 Feb 16;2(1):4
pubmed: 29872722
J Neurooncol. 2020 May;148(1):165-172
pubmed: 32346837
Med Oncol. 2013 Mar;30(1):408
pubmed: 23322521
Oncologist. 2014 May;19(5):453-8
pubmed: 24710307
Clin Neurol Neurosurg. 2018 Sep;172:151-159
pubmed: 30015053
Clin Exp Metastasis. 2017 Feb;34(2):185-196
pubmed: 28210910
Int J Mol Sci. 2016 Jul 05;17(7):
pubmed: 27399673
J Korean Neurosurg Soc. 2012 Sep;52(3):193-9
pubmed: 23115660
FASEB J. 2019 Jan;33(1):219-230
pubmed: 29995440
BMC Cancer. 2018 Jan 25;18(1):97
pubmed: 29370839
Expert Opin Pharmacother. 2005 Jun;6(7):1115-25
pubmed: 15957966
Adv Healthc Mater. 2019 Jun;8(11):e1801271
pubmed: 30997751
World J Surg Oncol. 2015 Feb 12;13:43
pubmed: 25886304
Clin Cancer Res. 2013 Dec 1;19(23):6404-18
pubmed: 24298071
Clin Breast Cancer. 2017 Feb;17(1):23-28
pubmed: 27569275
Biochem J. 2020 Feb 14;477(3):727-745
pubmed: 31957806
Breast. 2015 Nov;24 Suppl 2:S19-22
pubmed: 26238439
Cancer Chemother Pharmacol. 2013 Jul;72(1):201-7
pubmed: 23670641
Breast Cancer Res Treat. 2015 Nov;154(2):339-49
pubmed: 26520840
J Drug Deliv. 2013;2013:147325
pubmed: 23401780
Br J Cancer. 2001 Jan;84(2):157-63
pubmed: 11161370
Biomolecules. 2019 Jan 15;9(1):
pubmed: 30650622
Breast Cancer. 2009;16(1):88-92
pubmed: 18478315
Breast Cancer (Auckl). 2015 Sep 01;9(Suppl 1):23-34
pubmed: 26380552
Mol Cell Proteomics. 2015 Aug;14(8):2177-93
pubmed: 26041847
Exp Neurol. 2015 Nov;273:57-68
pubmed: 26247808
Mol Cancer Ther. 2011 Nov;10(11):2115-23
pubmed: 21885865
Breast Cancer Res. 2017 Apr 26;19(1):51
pubmed: 28446206
Clin Breast Cancer. 2006 Jun;7(2):164-6
pubmed: 16800978
J Neurosurg. 2011 Oct;115(4):730-6
pubmed: 21721878
J Natl Compr Canc Netw. 2005 Sep;3(5):693-703
pubmed: 16194457
J Neurooncol. 1997 Oct;35(1):55-64
pubmed: 9266441
Neurosurg Clin N Am. 2011 Jan;22(1):67-78, vii
pubmed: 21109151
Neuron. 2016 Jan 6;89(1):37-53
pubmed: 26687838
Neurosurg Rev. 2013 Jul;36(3):377-82
pubmed: 23262837
Blood. 2020 Aug 13;136(7):909-913
pubmed: 32294158
Clin Nucl Med. 2019 Feb;44(2):e96-e97
pubmed: 30516668
Nucleic Acids Res. 2008 Aug;36(13):4337-51
pubmed: 18586824
BMC Struct Biol. 2003 Nov 11;3:8
pubmed: 14609438
Nat Med. 2011 Nov 13;17(12):1641-5
pubmed: 22081024
Cancer Cell. 2015 Feb 9;27(2):163-75
pubmed: 25670078
Strahlenther Onkol. 2001 Apr;177(4):195-9
pubmed: 11370554
Clin Exp Metastasis. 2020 Jun;37(3):401-412
pubmed: 32279122
PLoS One. 2012;7(11):e50300
pubmed: 23209700
Neurol Clin. 2003 Feb;21(1):25-66
pubmed: 12690644
J Neurooncol. 2009 Jun;93(2):205-12
pubmed: 19043775
Clin Chim Acta. 2019 May;492:69-71
pubmed: 30771299
Oncotarget. 2017 Aug 16;8(42):73312-73328
pubmed: 29069871
Blood. 2019 Feb 14;133(7):697-709
pubmed: 30463995
Nat Rev Neurol. 2019 Mar;15(3):161-178
pubmed: 30783219
Anticancer Res. 2012 Nov;32(11):4655-62
pubmed: 23155227
Cancer Treat Rev. 2016 Feb;43:83-91
pubmed: 26827696
Mol Cancer. 2018 Feb 19;17(1):36
pubmed: 29455664
Curr Opin Oncol. 2010 Nov;22(6):627-35
pubmed: 20689429
Cancer Res Treat. 2017 Jul;49(3):748-758
pubmed: 27809457
No Shinkei Geka. 2015 Sep;43(9):819-23
pubmed: 26321696
Front Oncol. 2018 Apr 03;8:89
pubmed: 29670855
Breast J. 2018 May;24(3):424-425
pubmed: 29251377
Cell Cycle. 2008 Jul 1;7(13):1899-906
pubmed: 18604167
Mol Cancer. 2015 May 20;14:106
pubmed: 25987188
Oncotarget. 2017 Dec 21;9(2):2705-2714
pubmed: 29416803
Neuro Oncol. 2019 Mar 18;21(4):428-439
pubmed: 30418595
Clin Breast Cancer. 2015 Feb;15(1):66-72
pubmed: 25287959
Am J Case Rep. 2015 Aug 10;16:524-7
pubmed: 26258900
J Clin Neurosci. 2016 May;27:130-7
pubmed: 26778048
Brain Dev. 2019 Oct;41(9):817-819
pubmed: 31122803
Cell Cycle. 2015;14(9):1447-58
pubmed: 25789545
J BUON. 2015 Nov-Dec;20(6):1414-9
pubmed: 26854435
Cancer Res. 2021 Jun 15;81(12):3200-3214
pubmed: 33941612
Oncotarget. 2019 Oct 29;10(59):6334-6348
pubmed: 31695842

Auteurs

Khairul I Ansari (KI)

Division of Neurosurgery, Beckman Research Institute, City of Hope, Duarte, California.
Celcuity, Minneapolis, Minnesota.

Arunoday Bhan (A)

Division of Neurosurgery, Beckman Research Institute, City of Hope, Duarte, California.

Mika Saotome (M)

Department of Biomedical Sciences, University of North Dakota School of Medicine, Grand Forks, North Dakota.

Antariksh Tyagi (A)

Department of Biomedical Sciences, University of North Dakota School of Medicine, Grand Forks, North Dakota.

Bony De Kumar (B)

Department of Biomedical Sciences, University of North Dakota School of Medicine, Grand Forks, North Dakota.

Clara Chen (C)

Division of Neurosurgery, Beckman Research Institute, City of Hope, Duarte, California.

Motoki Takaku (M)

Department of Biomedical Sciences, University of North Dakota School of Medicine, Grand Forks, North Dakota.

Rahul Jandial (R)

Division of Neurosurgery, Beckman Research Institute, City of Hope, Duarte, California. rjandial@coh.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Autocrine GMCSF Signaling Contributes to Growth of HER2
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Communication cellulaire › Communication autocrine › Autocrine GMCSF Signaling Contributes to Growth of HER2
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Maladies du sein › Tumeurs du sein › Autocrine GMCSF Signaling Contributes to Growth of HER2
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › Autocrine GMCSF Signaling Contributes to Growth of HER2
questionsmedicales.fr › Phénomènes physiologiques › Croissance et développement › Croissance › Processus de croissance cellulaire › Prolifération cellulaire › Autocrine GMCSF Signaling Contributes to Growth of HER2
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Survie cellulaire › Autocrine GMCSF Signaling Contributes to Growth of HER2
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles biologiques › Modèles animaux de maladie humaine › Autocrine GMCSF Signaling Contributes to Growth of HER2
questionsmedicales.fr › Phénomènes génétiques › Expression des gènes › Autocrine GMCSF Signaling Contributes to Growth of HER2
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Facteurs de croissance hématopoïétique › Facteurs de stimulation des colonies › Facteur de stimulation des colonies de granulocytes et de macrophages › Autocrine GMCSF Signaling Contributes to Growth of HER2
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Autocrine GMCSF Signaling Contributes to Growth of HER2
questionsmedicales.fr › Maladies du système nerveux › Tumeurs du système nerveux › Tumeurs du système nerveux central › Tumeurs des méninges › Méningite carcinomateuse › Autocrine GMCSF Signaling Contributes to Growth of HER2
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Autocrine GMCSF Signaling Contributes to Growth of HER2
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines tumorales › Protéines oncogènes › Autocrine GMCSF Signaling Contributes to Growth of HER2
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Inhibiteurs de protéines kinases › Autocrine GMCSF Signaling Contributes to Growth of HER2
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › Récepteur ErbB-2 › Autocrine GMCSF Signaling Contributes to Growth of HER2
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Transduction du signal › Autocrine GMCSF Signaling Contributes to Growth of HER2
questionsmedicales.fr › Techniques d'investigation › Transplantation tumorale › Tests d'activité antitumorale sur modèle de xénogreffe › Autocrine GMCSF Signaling Contributes to Growth of HER2